

Reference:	FOI.14198.24
Subject:	Cancer treatment
Date of Request:	11 April 2024

Requested:

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
 - a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer
2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
3. How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?
 - a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer
4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
 - a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for questions 1, 3 and 4, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

However, in response to question 2, the UHB can confirm that no unique patients were treated with Nivolumab for early stage (resectable) Non-Small Cell Lung (NSCL) cancer, during the period 1 November 2023 to 31 March 2024.